Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | HTR1F | P30939 | 1/20 | 0.54 |
| ▸ | SCD | O00767 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18619477 | 0.84 | HTT (0.54) | HTTSMN1; SMN2LMNAHTR1AHTR1F | |
| SCHEMBL23351594 | 0.83 | ACHE (0.55) | — | |
| SCHEMBL10637192 | 0.82 | HTT (0.61) | HTTSMN1; SMN2LMNAHTR1AHTR1F | |
| SCHEMBL22491514 | 0.80 | MGLL (0.56) | HTR1AHTR1FHTR2ADRD3 | |
| SCHEMBL29734583 | 0.80 | MGLL (0.56) | HTR1AHTR1FHTR2ADRD3 | |
| SCHEMBL18763046 | 0.79 | HTT (0.55) | HTTSMN1; SMN2LMNAHTR1AHTR1F | |
| SCHEMBL21143169 | 0.78 | HTT (0.55) | HTTSMN1; SMN2LMNAHTR1AHTR1F | |
| SCHEMBL29688909 | 0.76 | HTR2A (0.46) | HTTSMN1; SMN2LMNAHTR1AHTR1F | |
| SCHEMBL20135089 | 0.76 | HTR2A (0.46) | HTTSMN1; SMN2LMNAHTR1AHTR1F | |
| SCHEMBL20135091 | 0.76 | HTR2A (0.46) | HTTSMN1; SMN2LMNAHTR1AHTR1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3345910-B1 | COMPOUND HAVING EFFECT OF INHIBITING PLATELET AGGREGATION AND SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING THROMBOTIC DISEASES, CONTAINING SAME | SHIN POONG PHARMACEUTICAL CO LTD (KR) | 2023-11-01 | — | — | EP | claimed |
| US-10730886-B2 | Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2020-08-04 | — | — | US | claimed |
| US-20180251472-A1 | Compound Having Effect Of Inhibiting Platelet Aggregation And Salt Thereof, And Composition For Preventing Or Treating Thrombotic Diseases, Containing Same | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2018-09-06 | — | — | US | claimed |
| EP-3345910-A1 | COMPOUND HAVING EFFECT OF INHIBITING PLATELET AGGREGATION AND SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING THROMBOTIC DISEASES, CONTAINING SAME | Shin Poong Pharmaceutical Co., Ltd. (KR) | 2018-07-11 | — | — | EP | claimed |
| EP-3345910-B1 | COMPOUND HAVING EFFECT OF INHIBITING PLATELET AGGREGATION AND SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING THROMBOTIC DISEASES, CONTAINING SAME | SHIN POONG PHARMACEUTICAL CO LTD (KR) | 2023-11-01 | — | — | EP | disclosed |
| EP-3345910-B1 | COMPOUND HAVING EFFECT OF INHIBITING PLATELET AGGREGATION AND SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING THROMBOTIC DISEASES, CONTAINING SAME | SHIN POONG PHARMACEUTICAL CO LTD (KR) | 2023-11-01 | — | — | EP | disclosed |
| US-10730886-B2 | Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2020-08-04 | — | — | US | disclosed |
| US-10730886-B2 | Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2020-08-04 | — | — | US | disclosed |
| US-20180251472-A1 | Compound Having Effect Of Inhibiting Platelet Aggregation And Salt Thereof, And Composition For Preventing Or Treating Thrombotic Diseases, Containing Same | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2018-09-06 | — | — | US | disclosed |
| EP-3345910-A1 | COMPOUND HAVING EFFECT OF INHIBITING PLATELET AGGREGATION AND SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING THROMBOTIC DISEASES, CONTAINING SAME | Shin Poong Pharmaceutical Co., Ltd. (KR) | 2018-07-11 | — | — | EP | disclosed |
| EP-3345910-A1 | COMPOUND HAVING EFFECT OF INHIBITING PLATELET AGGREGATION AND SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING THROMBOTIC DISEASES, CONTAINING SAME | Shin Poong Pharmaceutical Co., Ltd. (KR) | 2018-07-11 | — | — | EP | disclosed |
| WO-2017039395-A1 | COMPOUND HAVING EFFECT OF INHIBITING PLATELET AGGREGATION AND SALT THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING THROMBOTIC DISEASES, CONTAINING SAME | 신풍제약 주식회사 | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251472-A1 | Compound Having Effect Of Inhibiting Platelet Aggregation And Salt Thereof, And Composition For Preventing Or Treating Thrombotic Diseases, Containing Same | PLA2G7, JAK2, PF4 | HTT 842/4885SMN1; SMN2 3670/4885LMNA 2948/4885 |
| US-10730886-B2 | Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same | PLA2G7, JAK2, PF4 | HTT 842/4885SMN1; SMN2 3670/4885LMNA 2948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.